Taysha completes screening for Rett syndrome gene therapy trial; reports Q1 net loss of $17.6M

Taysha Gene Therapies, Inc.

Screening completed for first adult patient in Phase 1/2 REVEAL trial of TSHA-102 for Rett syndrome; dosing expected Q2 2023.
Initial available Phase 1/2 clinical data, primarily on safety, expected in Q2 2023.
Net loss for Q1 2023 was $17.6M ($0.28 per share) vs. $50.3M ($1.32 per share) in Q1 2022.
Cash and equivalents $63.4M as of March 31, 2023; expected to fund operations into Q1 2024.
FDA meeting request for TSHA-120 (GAN) regulatory path expected Q2 2023; meeting anticipated Q3.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Taysha Gene Therapies, Inc. reported financial results for quarter ended March 31, 2023.

Period: quarter ended March 31, 2023
Result: reported results

Exact text from the filing

Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS), today reported financial results for the first quarter ended March 31, 2023, and provided a corporate update.

View on SEC.gov

Browse all earnings releases →

Taysha Gene Therapies, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-145197

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.